Publication:

HbA1c as screening biomarker of dyslipidemia in type 2 diabetes mellitus patients

Background Patients with diabetes are considered to be at high risk for dyslipidemia and hypertension and therefore vulnerable to cardiovascular diseases. This study describes the possible role of Glycated Hemoglobin (HbA1c) and serum lipid profile as a biomarker for detecting cardiovascular diseases. The aim of present work is to study the role of HbA1c as a screening biomarker for dyslipidemia in patients with type 2 Diabetes Mellitus (T2DM).

Methods Present study consists of 100 Type 2 DM patients between age 30-75 years along with age and sex matched 100 healthy controls. Fasting Blood samples were collected from all participants for measuring lipid profile, blood sugar (FBS) and HbA1c.

Results Present study revealed a significantly increased level of glycated hemoglobin (HbA1c) in cases compared to control. HbA1c showed direct and significant correlations with cholesterol, triglycerides and LDL and inverse correlation with HDL in cases when compared to controls.

Conclusions HbA1c can be used as a potential biomarker for the prediction of Dyslipidemia and CVD.